Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer. (2020)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41416-020-01046-6
PubMed Identifier: 32913288
Publication URI: http://europepmc.org/abstract/MED/32913288
Type: Journal Article/Review
Volume: 123
Parent Publication: British journal of cancer
Issue: 10
ISSN: 0007-0920